Cullinan Therapeutics, Inc.
CGEM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $103 | $73 | $77 | $83 |
| Short-Term Investments | $229 | $193 | $227 | $316 |
| Receivables | $0 | $0 | $0 | $3 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $10 | $10 | $14 | $13 |
| Total Curr. Assets | $342 | $276 | $318 | $415 |
| Property Plant & Equip (Net) | $2 | $2 | $2 | $2 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $140 | $242 | $259 | $204 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $142 | $244 | $262 | $207 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $484 | $520 | $580 | $622 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $3 | $2 |
| Short-Term Debt | $1 | $1 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $30 | $24 | $23 | $28 |
| Total Curr. Liab. | $33 | $28 | $27 | $31 |
| LT Debt | $0 | $0 | $0 | $1 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $1 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $2 | $2 | $2 |
| Total Liabilities | $33 | $28 | $28 | $31 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$537 | -$487 | -$417 | -$368 |
| AOCI | $1 | $1 | $1 | -$0 |
| Other Equity | $988 | $978 | $968 | $959 |
| Total Equity | $451 | $492 | $552 | $590 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $484 | $520 | $580 | $622 |
| Net Debt | -$102 | -$71 | -$75 | -$81 |